While the KEYNOTE-061 trial confirmed a better outcome with pembrolizumab in patients with PD-L1-positive tumours [13] data from the JAVELIN Gastric 300 and ATTRACTION-2 trials did not support the concept of PD-L1 positivity as a predictive response marker to ICIs [14,15]. The gene discussed is CD274; the disease is neoplasm.